{"id":942100,"date":"2026-03-04T19:53:16","date_gmt":"2026-03-05T00:53:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/"},"modified":"2026-03-04T19:53:16","modified_gmt":"2026-03-05T00:53:16","slug":"castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/","title":{"rendered":"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB"},"content":{"rendered":"<div class=\"mw_release\">\n<p>FRIENDSWOOD, Texas, March  04, 2026  (GLOBE NEWSWIRE) &#8212; Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma\u2019s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix.<\/p>\n<p>\u201cThe initial reports from the same prospective, multicenter study confirmed the performance of DecisionDx-Melanoma to both (i) impact sentinel lymph node biopsy (SLNB) decision-making and (ii) identify patients at low risk of nodal metastasis,\u201d said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, at Castle Biosciences. \u201cThe data being presented at SSO 2026 further extend this growing body of evidence supporting the use of DecisionDx-Melanoma to guide risk-aligned management decisions consistent with National Comprehensive Cancer Network\u00ae guideline risk thresholds, including whether to forgo, consider or pursue SLNB.\u201d<\/p>\n<p>Castle will share the following ePoster at SSO: <strong>EP49<\/strong>: <strong>The integrated 31-gene expression profile test identifies patients with T1b\u2013T2a cutaneous melanoma who can safely avoid sentinel lymph node biopsy<\/strong>.<\/p>\n<p>DecisionDx-Melanoma\u2019s i31-SLNB algorithm integrates the independent 31-GEP score with key clinicopathologic factors, including Breslow thickness, ulceration, mitotic rate and age. This integrated approach was developed and independently validated to provide more precise risk estimation than staging criteria alone. By combining tumor biology with traditional clinical features, the algorithm generates a personalized likelihood of SLN positivity, supporting risk-aligned shared decision-making for SLNB, a surgical staging procedure commonly used to assess nodal metastasis risk.<\/p>\n<p>ePosters will be available for viewing in the SSO 2026 Exhibit Hall, on the SSO Annual Meeting website and within the SSO Mobile App. The ePoster gallery will be accessible to registered attendees.<\/p>\n<p>For more information on DecisionDx-Melanoma and the poster above, please visit Castle at booth #321.<\/p>\n<p>\n        <strong>About DecisionDx-Melanoma <\/strong><br \/>\n        <br \/>DecisionDx-Melanoma is a gene expression profile (GEP) test designed to analyze tumor biology to deliver a personalized risk assessment for patients with stage I\u2013III cutaneous melanoma, enhancing risk stratification beyond American Joint Committee on Cancer (AJCC) staging alone. By combining molecular insights with select clinicopathologic features, the test provides two distinct outputs: a personalized risk of sentinel lymph node (SLN) positivity and a personalized risk of recurrence and\/or metastasis. This clinically actionable information is designed to help guide risk-aligned patient management decisions, including SLN biopsy consideration, follow-up intensity, imaging and referrals.<\/p>\n<p>DecisionDx-Melanoma is supported by more than 50 peer-reviewed publications, including prospective studies and meta-analyses, and was developed in collaboration with more than 100 leading U.S. institutions. The test has been clinically validated in more than 10,000 patient samples, ordered more than 220,000 times since launch, and has been shown to be associated with improved patient survival. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8k5l3i7H3VEPIMP5RGcdGUPC2ycQQt8vXNZa2v30uqcsWMVMeq_vPBS9KqvEAyUN3STPbOSNtp6nKzyq3xYNsfuFqqchlgBghQX7lYI31Ten-KJCOQLIyYkojaLCTgBs8m4eTyAdhvw6q3JfQg1ZtX60Ss1sHFJj1__YGWF0Nqs=\" rel=\"nofollow\" target=\"_blank\">www.CastleBiosciences.com<\/a>.<\/p>\n<p>\n        <strong>About Castle Biosciences <\/strong><br \/>\n        <br \/>Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.<\/p>\n<p>We put people first\u2014empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8k5l3i7H3VEPIMP5RGcdGUPC2ycQQt8vXNZa2v30uqeGNF8s22uISX9JIvVpi5SfLBTIjcK6f_4ufT-GGo9yHr_YjQKrdJZfZpkS19Pq1WbGO0z_PQQLJz9cw2lHVxN9\" rel=\"nofollow\" target=\"_blank\">www.CastleBiosciences.com<\/a> and connect with us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZGKSebyjVQa7-a85Iv1nxDnqdOrKPKVbN_58aY2GLSDSDa3HY0TZCkPu_tGVhHns1r7eVz6iFIKXE8LY-xEnbcECzqE5ETixs0mxsEMDctfcS8rLWLYh6zqyDSIKgi77\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xW1LDU63CVttSjSj7FqBJHnsOyqTp1TDJeq5EZwJVvSDnQ8quoe55dcnnD-9KSrV79ataIh8oGYzGNpfaxG4CfWL2k488Ynm3rkewpyKjDyR3TGGiT4UJZUFXpSOghRf\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=chct_UNjPJvQ0LF1WQS0meG-v1w95JXstjXSjCKzfnXoAteC1rs07aeb8bGIBZTjNXZ2fgJlcWUVKa9dac9k7DGLt22Ag32_gz0GlL6Yz6M=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a> and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LTZdQ4peZ4loFzHM609qGqpFQ7h0REp2Xx2grw8uqI72i3Yo9PC3JHY6df3mRvaAx_VNN2B9m1U2lop1TfJ96cv2_YoM2eFLVOUss208axw=\" rel=\"nofollow\" target=\"_blank\">X<\/a>.\u202f<\/p>\n<p>DecisionDx-Melanoma, DecisionDx-CM<em>Seq<\/em>, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM<em>Seq<\/em> are trademarks of Castle Biosciences, Inc.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the \u201csafe harbor\u201d created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the ability of DecisionDx-Melanoma\u2019s i31-SLNB test to (i) provide more precise risk estimation than staging criteria alone, (ii) support risk-aligned shared decision-making for SLNB and (iii) identify patients at low risk of nodal metastasis. The words \u201cdesigned,\u201d \u201cmay\u201d, \u201ccan\u201d, and similar expressions are intended to identify forward intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to certain patients; and the risks set forth under the heading \u201cRisk Factors\u201d in our Annual Report on Form 10-K for the year ended December 31, 2025, and our subsequent Quarterly Reports on Form 10-Q, each as filed or to be filed with the SEC, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.<\/em>\n      <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Camilla Zuckero<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SzrX-o1OuzrxPa77lqcyHCRXAuf7gIXRNMJ_Fr5Ju7uojxMRRQ1D0xZlbYGciKSBXeUJVSo6ngzC_r6092ZoSGUPiRN83d2xYJWhUjp3S_U9OYTBpmxQDaX54aNcODr0\" rel=\"nofollow\" target=\"_blank\">czuckero@castlebiosciences.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Allison Marshall<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-A6GuRIoDWbTPc8IVUS2YgtF1rsEvs-4qKQrUK1TogsnXvCGeEtHe1s9NDDri_5WBCTI_FcZXeOWLPdycIRET2-q2D3KsZYDraEXtiDM2SscVX1rmZgGOtU2jqEieQfDV2SxWipJLZTZCmgYCM_4QQ==\" rel=\"nofollow\" target=\"_blank\">amarshall@castlebiosciences.com<\/a><\/p>\n<p>\n        <strong>Source: <\/strong>Castle Biosciences, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmQ5NDZlZDgtNzBhZC00ZTY2LTlkNjctZjIwZmRlOWM3ZGFhLTExMDc2NDUtMjAyNi0wMy0wNC1lbg==\/tiny\/Castle-Biosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) &#8212; Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma\u2019s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. \u201cThe initial reports from the same prospective, multicenter study confirmed the performance of DecisionDx-Melanoma to both (i) impact sentinel lymph node biopsy (SLNB) decision-making and (ii) identify patients at low risk of nodal metastasis,\u201d said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, at Castle Biosciences. \u201cThe data being presented at SSO 2026 further extend this growing body of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942100","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) &#8212; Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma\u2019s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. \u201cThe initial reports from the same prospective, multicenter study confirmed the performance of DecisionDx-Melanoma to both (i) impact sentinel lymph node biopsy (SLNB) decision-making and (ii) identify patients at low risk of nodal metastasis,\u201d said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, at Castle Biosciences. \u201cThe data being presented at SSO 2026 further extend this growing body of &hellip; Continue reading &quot;Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T00:53:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB\",\"datePublished\":\"2026-03-05T00:53:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/\"},\"wordCount\":906,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/\",\"name\":\"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=\",\"datePublished\":\"2026-03-05T00:53:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/","og_locale":"en_US","og_type":"article","og_title":"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB - Market Newsdesk","og_description":"FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) &#8212; Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma\u2019s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. \u201cThe initial reports from the same prospective, multicenter study confirmed the performance of DecisionDx-Melanoma to both (i) impact sentinel lymph node biopsy (SLNB) decision-making and (ii) identify patients at low risk of nodal metastasis,\u201d said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, at Castle Biosciences. \u201cThe data being presented at SSO 2026 further extend this growing body of &hellip; Continue reading \"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-05T00:53:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB","datePublished":"2026-03-05T00:53:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/"},"wordCount":906,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/","name":"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=","datePublished":"2026-03-05T00:53:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTk4NCM3NDY4MjAwIzIwOTYwNzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-to-present-data-at-sso-2026-on-decisiondx-melanomas-i31-slnb-identifying-t1b-t2a-melanoma-patients-who-may-safely-avoid-slnb\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Castle Biosciences to Present Data at SSO 2026 on DecisionDx\u00ae-Melanoma\u2019s i31-SLNB, Identifying T1b\u2013T2a Melanoma Patients Who May Safely Avoid SLNB"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942100"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942100\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}